Awareness of the importance of the CD79a marker for the development of B lymphocytes and its significance in EGIL classification makes assessment of B-ALL very challenging in cases of complete or partial lack of expression of this marker. This evidence concerns the gene CD79A and acute lymphoblastic leukemia.